THYPINONE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYPINONE is a small-molecule injectable product originally approved by Abbott in 1976 with an unknown mechanism of action and indication profile. As a legacy NDA product approaching loss of exclusivity, it represents a mature therapeutic with limited modern clinical development.
LOE Approaching
Approaching loss of exclusivity with low commercial visibility (0 linked jobs); expect contraction in brand team size and transition to generic defense or portfolio rationalization mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYPINONE has zero linked job openings and approaches loss of exclusivity, making it a poor career growth opportunity. Professionals assigned to this product should expect limited advancement prospects and may be better positioned pursuing roles on growth-stage or newly launched therapeutics.
Brand ManagerProduct Manager
Worked on THYPINONE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.